Low Dose Semaglutide While Breastfeeding: What the Milk Studies, the Label, and LactMed Actually Show
People asking about low dose semaglutide while breastfeeding usually want one thing: does the drug reach the baby? One small milk study found none. The label still says the data are missing, and the tablet form is a different story.
0 of 8
WOMEN ON INJECTED SEMAGLUTIDE WITH DETECTABLE DRUG IN THEIR MILK (DIAB ET AL., 2024)
1.26%
WORST-CASE RELATIVE INFANT DOSE, AGAINST A USUAL 10% THRESHOLD
Tablets
THE ONE SEMAGLUTIDE FORM THE WEGOVY LABEL SAYS NOT TO USE WHILE BREASTFEEDING
Pregnancy weight does not leave on a schedule, and the months of night feeds are not the easiest time to diet. So the question comes up in clinics and forums alike: could a small dose of semaglutide help, and would it be safe for a nursing baby?
The evidence on low dose semaglutide while breastfeeding is thin but no longer empty. There is one direct milk study for injected semaglutide, a label that changed in 2026 to treat tablets and injections differently, an NIH LactMed entry, and two systematic reviews that describe how little anyone knows. This article walks through each, says plainly where the data stop, and leaves dosing decisions where they belong, with a prescriber.
Key takeaways
- •In a 2024 study (Diab et al., Nutrients), semaglutide was not detected in milk from eight women using the subcutaneous injection, with an assay that could detect 1.7 ng/mL.
- •The same study put the worst-case relative infant dose at 1.26%, below the conventional 10% safety threshold for medicines in breast milk.
- •The Wegovy label says breastfeeding is not recommended with Wegovy tablets, because the absorption enhancer SNAC appears in human milk; the injection does not contain SNAC.
- •No study has measured the effect of semaglutide on milk supply or long-term infant growth, and no trial has tested a specific low dose during lactation.
- •A 2026 review found that only 4.4% of guideline recommendations on diabetes drugs in breastfeeding were based on clinical evidence.
Can you take low dose semaglutide while breastfeeding?
Low dose semaglutide while breastfeeding is not ruled out by the label for the injection, but it is not established as safe either. The Wegovy prescribing information asks prescribers and mothers to weigh the benefits of breastfeeding against the mother's clinical need for the drug and any possible effects on the infant. That is a judgment call, not a green light.
The current Wegovy label is direct about the gap for the injection: "There are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production." A small academic milk study, covered below, has since measured part of that gap.
NIH's Drugs and Lactation Database takes a somewhat firmer view. The LactMed semaglutide entry states that semaglutide "was not detectable in the milk of mothers taking the drug subcutaneously" and that their breastfed infants had no adverse effects. LactMed adds that some experts recommend close monitoring of infant growth, developmental milestones and the mother's own nutrition.
Does semaglutide pass into breast milk?
Injected semaglutide did not show up in human milk in the only study that measured it directly. Diab and colleagues at Texas Tech, writing in Nutrients in 2024, tested milk from eight women held in the InfantRisk Center Human Milk biorepository.
The milk samples were collected at 0, 12 and 24 hours after a semaglutide injection and analysed with high-resolution liquid chromatography-mass spectrometry. The authors report plainly that "Semaglutide was not detected in any of the collected human milk samples." The assay could detect semaglutide down to 1.7 ng/mL and quantify it from 5.7 ng/mL.
How sensitive were the milk tests? Assay thresholds (ng/mL)
Semaglutide: Diab H et al., Nutrients 2024. Tirzepatide: ZEPBOUND prescribing information, section 8.2. Lower is more sensitive.
"Not detected" means below the limit of detection, not proven zero.
Why so little? The Wegovy label gives two properties that fit the finding. Semaglutide is a large peptide, with a molecular weight of 4113.58 g/mol, and it is more than 99% bound to albumin in the blood. These properties are consistent with the result, but the Diab study did not test the mechanism directly.
The study has clear limits. It included eight women, sampled milk over 24 hours rather than across a full weekly dosing cycle, and did not follow the infants. The authors themselves list "long-term infant outcomes, the safety of maternal nutrient intake, and the nutrient content of breast milk" as unanswered questions.
How much semaglutide could a breastfed baby get?
Even in a worst-case calculation, a breastfed baby's estimated exposure to injected semaglutide was small. Because the milk test found nothing, Diab and colleagues assumed every sample sat right at the limit of quantification and calculated a relative infant dose (RID) from there, accounting for semaglutide's long-acting profile and bioavailability.
Worst-case relative infant dose for injected semaglutide (%)
Diab H et al., Nutrients 2024. The 10% line is the conventional threshold the authors compared against.
The maximum projected RID was 1.26%, which the authors describe as "far below the standard 10% safety threshold." Their conclusion was that semaglutide concentrations in milk "are unlikely to pose clinical concerns for breastfed infants." That is a reasonable reading of a small pharmacokinetic study. It is not the same as an outcome study that weighed and tracked babies for months.
Why are semaglutide tablets not recommended while breastfeeding?
Semaglutide tablets are not recommended during breastfeeding because of their absorption enhancer, not because of semaglutide itself. Oral semaglutide is formulated with SNAC (salcaprozate sodium), which helps the peptide get through the stomach wall.
The 2026 Wegovy label describes a clinical lactation study with the oral formulation in which semaglutide in milk was below the lower limit of quantification. The problem was the excipient: "SNAC and/or its metabolites are present in human milk." Because infants may clear SNAC more slowly than adults, the label concludes that breastfeeding "is not recommended during treatment with WEGOVY tablets," and it points out that the injection does not contain SNAC.
LactMed reaches the same place from its own review, stating that "Only injectable forms of semaglutide should be used during breastfeeding." For anyone comparing formats more generally, our explainer on the GLP-1 pill versus the weekly injection covers SNAC, bioavailability and the empty-stomach rule in more detail.
What about tirzepatide while breastfeeding?
Tirzepatide has a sponsor-run milk study that found very little drug in breast milk after one 5 mg dose. The Zepbound label summarizes it: 11 healthy lactating women each received a single subcutaneous 5 mg dose, and their milk was sampled over 28 days.
Tirzepatide milk samples after a single 5 mg dose (n = 171 samples)
ZEPBOUND prescribing information, section 8.2 (DailyMed). Limit of detection 4 ng/mL.
- Undetectable
- Detectable
Tirzepatide was undetectable in 164 of 171 samples. Over the 28-day window, the remaining 7 samples added up to less than 0.02% of the mother's dose, and the last measurable level appeared 5 days after the injection. The label adds that there are no data on effects in breastfed infants or on milk production.
The LactMed tirzepatide entry notes that tirzepatide "is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg," and advises caution, "especially while nursing a newborn or preterm infant." A single-dose study cannot show what happens after weeks of regular dosing, so the two drugs sit in a similar place: low measured transfer, no infant outcome data. For how the two compare on dose generally, see microdose semaglutide vs tirzepatide.
Why does the guidance seem so inconsistent?
Guidance on diabetes and weight drugs during breastfeeding is inconsistent because very little of it rests on human data. A 2026 systematic review by Richardson and colleagues in Clinical Pharmacology and Therapeutics found that only 5 of 20 type 2 diabetes drugs had any clinical data on transfer from plasma to breast milk. Semaglutide was one of the five.
Guideline recommendations on diabetes drugs during breastfeeding (%)
Richardson K et al., Clin Pharmacol Ther 2026 (systematic review of guidelines and pharmacokinetic studies).
Most recommendations (78%) advised against antiglycemic drugs while breastfeeding, but only 4.4% were based on clinical evidence, and just 51.7% gave explicit guidance at all. In other words, a cautious "avoid" is often the default when nobody has measured anything, rather than a sign that harm was found.
A second 2026 review, by Ozbek and colleagues in Diabetes, Obesity and Metabolism, screened the literature to 23 September 2025 and included 36 studies on GLP-1 and GLP-1/GIP drugs around pregnancy and lactation. On breastfeeding specifically it found that "Lactation data were sparse," with the one semaglutide milk study as the main entry.
What is considered a low dose of semaglutide?
A low dose of semaglutide usually means the starting steps of the labeled schedule, 0.25 mg or 0.5 mg once weekly. The Wegovy label starts every adult at 0.25 mg for weeks 1 to 4, then raises the dose every 4 weeks to the usual 2.4 mg maintenance dose.
Labeled once-weekly Wegovy injection schedule (mg)
WEGOVY prescribing information, Table 1 (DailyMed). Not specific to lactation.
No lactation study compared doses, so there is no evidence that a lower dose is safer for a nursing infant than a higher one, or the reverse. In the dose-ranging trial below, gastrointestinal side effects were dose-related, which matters when a new parent needs to keep eating and drinking. Our guide to low dose semaglutide for weight loss goes through each step of the schedule in more detail.
Does a low dose of semaglutide work?
Low doses of semaglutide produced meaningful weight loss in trials, though less than higher doses. The clearest dose-by-dose data come from a 52-week phase 2 trial by O'Neil and colleagues in the Lancet in 2018, which gave 957 adults with obesity once-daily injections from 0.05 mg to 0.4 mg.
Mean weight loss at week 52 by once-daily semaglutide dose (%)
O'Neil PM et al., Lancet 2018 (957 adults with obesity, without diabetes). No participants were breastfeeding.
Mean weight loss was 6.0% on 0.05 mg, 8.6% on 0.1 mg, 11.6% on 0.2 mg, 11.2% on 0.3 mg and 13.8% on 0.4 mg, compared with 2.3% on placebo. The most common side effects were "dose-related gastrointestinal symptoms, primarily nausea." These were daily doses in people who were not breastfeeding, so the numbers cannot be read across to a postpartum weekly regimen.
Can low dose semaglutide cause pancreatitis or other problems?
The Wegovy label does not set a dose below which pancreatitis risk disappears. It warns that "Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists," and tells patients to stop the drug if pancreatitis is suspected. Persistent, severe abdominal pain, sometimes spreading to the back, is the warning sign.
Two practical points matter more in the postpartum months. First, milk supply: the label states there are no data on semaglutide's effect on milk production, and appetite suppression plus nausea can cut food and fluid intake at the time a nursing parent needs more of both. Whether that changes supply has not been established in any study. Our piece on nutrients and hydration on a GLP-1 covers the gaps that tend to open up.
Second, timing: semaglutide has an elimination half-life of about 1 week and stays in circulation for about 5 to 7 weeks after the last injection, according to the label. Stopping does not clear it quickly, and the label separately advises stopping at least 2 months before a planned pregnancy. More on the pancreas question is in our article on GLP-1 microdosing and pancreatitis.
So what does the evidence support?
The evidence supports a narrow conclusion. Injected semaglutide was not found in the milk of a small group of women, a worst-case infant dose estimate came out low, and LactMed describes no infant problems in the reports it reviewed. Semaglutide tablets are a separate case: the label advises against breastfeeding with them because of SNAC.
What the evidence does not cover yet is just as important. Nobody has measured milk supply on semaglutide, followed breastfed infants' growth over months, compared low and high doses during lactation, or studied newborns and preterm babies specifically. Those are the questions a parent and prescriber are weighing when they decide.
Injected semaglutide barely reaches breast milk in the data so far. The tablet should not be used while nursing. Supply and long-term infant outcomes remain unmeasured.
Frequently asked questions
Is low dose semaglutide safe while breastfeeding?
Safety during breastfeeding has not been established in a clinical trial at any dose. The best data come from a 2024 study of milk from eight women on injected semaglutide, which found no detectable drug and estimated a worst-case relative infant dose of 1.26%, well under the usual 10% threshold. The Wegovy label says there are no data on effects in breastfed infants or on milk production, so the decision is one to make with a prescriber.
Does semaglutide pass into breast milk?
Injected semaglutide was not detected in human milk in the one study that measured it directly. That study, by Diab and colleagues in Nutrients in 2024, used an assay with a limit of detection of 1.7 ng/mL. Semaglutide is a large molecule of 4113.58 g/mol and is more than 99% bound to albumin in blood, which fits with little of it reaching milk.
Can you take Wegovy tablets or Rybelsus while breastfeeding?
No. The Wegovy label advises that breastfeeding is not recommended during treatment with Wegovy tablets. Oral semaglutide contains the absorption enhancer SNAC (salcaprozate sodium), and SNAC or its metabolites are present in human milk. LactMed states that only injectable forms of semaglutide should be used during breastfeeding.
What is considered a low dose of semaglutide?
On the Wegovy label, the starting dose is 0.25 mg once weekly for weeks 1 to 4, followed by 0.5 mg, 1 mg and 1.7 mg before the usual 2.4 mg maintenance dose. Doses at or below the early steps are what people usually mean by low dose. There is no separate lactation dose, and none of the milk studies compared doses.
Does a low dose of semaglutide work for weight loss?
Low doses produced real but smaller weight loss in trials. In a 52-week dose-ranging trial of once-daily semaglutide in 957 adults with obesity, mean weight loss was 6.0% on 0.05 mg and 13.8% on 0.4 mg, versus 2.3% on placebo. None of the participants were breastfeeding, so these results describe people who were not lactating.
Can low dose semaglutide cause pancreatitis?
The Wegovy label warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing forms, has been observed with GLP-1 receptor agonists. The label does not set a dose below which this risk disappears. Persistent severe abdominal pain, sometimes spreading to the back, is a reason to stop and seek care.
Does semaglutide affect breast milk supply?
The effect of semaglutide on milk supply is unknown. The Wegovy label states that there are no data on the effects on milk production, and the Diab study authors listed maternal nutrient intake and milk nutrient content as open questions. Because semaglutide reduces appetite, eating and drinking enough is worth tracking.
Is tirzepatide different from semaglutide while breastfeeding?
Tirzepatide has its own small milk study, which the Zepbound label summarizes. After a single 5 mg dose in 11 lactating women, tirzepatide was undetectable in 164 of 171 milk samples, and the detectable amount over 28 days was less than 0.02% of the mother's dose. LactMed advises caution, especially with a newborn or preterm infant.
Clinical references
- Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024. doi:10.3390/nu16172886
- Richardson K, Kiptoo J, Mpora Odongkara B, Ojara FW, Waitt C. Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines. Clinical Pharmacology and Therapeutics. 2026. doi:10.1002/cpt.70211
- Ozbek L, Shah E, Al-Shiab R, et al. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70699
- Semaglutide. Drugs and Lactation Database (LactMed). National Institute of Child Health and Human Development. PMID 30000039
- Tirzepatide. Drugs and Lactation Database (LactMed). National Institute of Child Health and Human Development. PMID 35759552
- WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, National Library of Medicine. Accessed October 15, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. Accessed October 15, 2026. dailymed.nlm.nih.gov
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018. doi:10.1016/S0140-6736(18)31773-2
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the physician, prescriber, pediatrician, lactation consultant, or pharmacist responsible for your care and your baby's care. Semaglutide is a prescription medicine, and its safety during breastfeeding has not been established in clinical trials. Charts show values reported in the cited studies and prescribing information. Do not start, change, or stop a medicine while breastfeeding without your prescriber. Contact your baby's clinician promptly about poor feeding, fewer wet diapers, unusual sleepiness, or slow weight gain, and seek care for severe or persistent abdominal pain or repeated vomiting.